BioSpace News Archive

In November, Chinese researcher He Jiankui of the Southern University of Science and Technology of China announced he had used CRISPR to alter the embryos of seven couples to make them resistant to HIV. To date, a set of twins were born and there is another pregnancy. This was met by near-universal condemnation in the global scientific community.

Shares of GlaxoSmithKline took a slight dip Wednesday afternoon after the U.S. Food and Drug Administration approved Mylan NV’s generic version of Advair Diskus, a staple blockbuster drug in the U.K. pharmaceutical company’s pipeline.

On January 3, Bristol-Myers Squibb announced it was buying Celgene for $74 billion. This would create a giant company with a significant pipeline focused on oncology, inflammatory and immunologic diseases, and cardiovascular disease. As the companies release their fourth-quarter results, more details about the combined companies’ plans are emerging.

Have you ever experienced a career epiphany but lacked the resolve to act on it? Don’t feel bad, especially if “acting on it” meant leaving a secure, albeit unfulfilling, job for a new career in a different industry.

The first treatment in this final study prior to the application for marketing authorization for the gp-ASIT+™ product candidate on the German market was undertaken on schedule at the Memmingen medical center in Germany

One side effect of getting older is a weakening immune system.

Janssen Pharmaceutical, a Johnson & Johnson company, inked a worldwide collaboration and license deal with MeiraGTx to develop, manufacture and commercialize a portfolio of drugs for inherited retinal diseases.

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

Immunicum AB has, as previously announced, implemented a share issue with preferential rights for the Company’s existing shareholders.

Leading provider of premium medical devices and hygiene products successfully launchesSuprasorb® CNP P3 and Debrisoft Pad for the first time in the region